Home

Search

Pathway AI

Account ⋅ Sign Out

Table of contents

Chronic myeloid leukemia

Definition
CML is a malignant clonal disorder of hematopoietic stem cells resulting in unregulated growth of myeloid cells in the bone marrow.
1
Pathophysiology
CML is caused by a chromosomal abnormality termed as Philadelphia chromosome, which results from the presence of BCR-ABL oncogene.
2
Disease course
Clinical manifestations include fatigue, weight loss, abdominal fullness, bleeding, purpura, splenomegaly, leukocytosis, anemia, and thrombocytosis. Disease progression may lead to bone pain, hepatosplenomegaly, severe anemia, infections, lymphadenopathy, CNS disease, and increased risk of death.
2
Prognosis and risk of recurrence
CML is associated with a mortality crude rate of 0.78.
3
Key sources
The following summarized guidelines for the evaluation and management of chronic myeloid leukemia are prepared by our editorial team based on guidelines from the British Society for Haematology (BSH 2020), the European Society of Medical Oncology (ESMO 2017), and the American Academy of Family Physicians (AAFP 2014).
1
2
3
4
5
6

Guidelines

1.Screening and diagnosis

Differential diagnosis: take into consideration the common causes, such as infection, inflammation, and stress response, when evaluating patients with leukocytosis.
B
Create free account

2.Classification and risk stratification

Prognostic assessment: consider calculating the EUTOS Long-Term Survival score to inform prognosis.
C

3.Diagnostic investigations

Diagnostic blood tests: as per ESMO 2017 guidelines, recognize that the diagnosis in most cases can be made on the basis of a characteristic blood count and differential (excessive granulocytosis with a typical left shift of granulopoiesis).
E

More topics in this section

  • Further evaluation

4.Diagnostic procedures

Bone marrow aspiration: obtain bone marrow aspiration at diagnosis for full karyotype analysis and to confirm the phase of the disease.
B

More topics in this section

  • Immunohistochemistry

  • Cytogenetic analysis

  • Mutational analysis

5.Medical management

Management of chronic phase, front-line regimens, BSH: offer imatinib as first-line therapy in most adult and pediatric patients with CML in chronic phase.
A
Show 2 more

More topics in this section

  • Management of chronic phase (prevention of complications)

  • Management of chronic phase (treatment monitoring)

  • Management of chronic phase (treatment discontinuation)

  • Management of resistant/refractory disease

  • Management of accelerated/blast phase

  • Management of infection

6.Specific circumstances

Pregnant patients: ensure that females with CML wishing to conceive do not have a previous TKI resistance and ideally have maintained MR4 for at least 12 months before considering discontinuation.
B
Show 3 more

7.Follow-up and surveillance

Surveillance for secondary malignancies: obtain serial CBC monitoring and age- and sex-specific cancer screening since leukemia survivors are at increased risk of secondary malignancies.
B